{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:36:19Z","timestamp":1793090179898,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00228-022-03430-y","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:43:28Z","timestamp":1671281008000},"page":"279-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)\u2013based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials"],"prefix":"10.1007","volume":"79","author":[{"given":"Yingchao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"key":"3430_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1146\/annurev-med-042220-020814","volume":"73","author":"YC Lee","year":"2022","unstructured":"Lee YC, Dore MP, Graham DY (2022) Diagnosis and treatment of Helicobacter pylori infection. Annu Rev Med 73:183\u2013195. https:\/\/doi.org\/10.1146\/annurev-med-042220-020814","journal-title":"Annu Rev Med"},{"issue":"9","key":"3430_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","volume":"64","author":"K Sugano","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, Faculty members of Kyoto Global Consensus C, (2015) Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64(9):1353\u20131367. https:\/\/doi.org\/10.1136\/gutjnl-2015-309252","journal-title":"Gut"},{"key":"3430_CR3","doi-asserted-by":"publisher","unstructured":"El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, Crowe SE, Elfant A, Haas T, Hapke RJ, Graham DY (2018) Houston Consensus Conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol 16 (7):992\u20131002 e1006. https:\/\/doi.org\/10.1016\/j.cgh.2018.03.013","DOI":"10.1016\/j.cgh.2018.03.013"},{"key":"3430_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17070","author":"D Ang","year":"2022","unstructured":"Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, Lin KW, Krishnasamy-Balasubramanian JK, Wong YJ, Kumar R, R R, Tan Y, Ong PJ, Tan YJ, Li JW, Kwek AB, Ang TL, (2022) Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther. https:\/\/doi.org\/10.1111\/apt.17070","journal-title":"Aliment Pharmacol Ther"},{"issue":"29","key":"3430_CR5","doi-asserted-by":"publisher","first-page":"9912","DOI":"10.3748\/wjg.v20.i29.9912","volume":"20","author":"SM Smith","year":"2014","unstructured":"Smith SM, O\u2019Morain C, McNamara D (2014) Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 20(29):9912\u20139921. https:\/\/doi.org\/10.3748\/wjg.v20.i29.9912","journal-title":"World J Gastroenterol"},{"issue":"8953","key":"3430_CR6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/s0140-6736(95)92962-2","volume":"345","author":"W de Boer","year":"1995","unstructured":"de Boer W, Driessen W, Jansz A, Tytgat G (1995) Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 345(8953):817\u2013820. https:\/\/doi.org\/10.1016\/s0140-6736(95)92962-2","journal-title":"Lancet"},{"key":"3430_CR7","doi-asserted-by":"publisher","unstructured":"Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E (2018) Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 155(5):1372\u20131382 e1317.\u00a0https:\/\/doi.org\/10.1053\/j.gastro.2018.07.007","DOI":"10.1053\/j.gastro.2018.07.007"},{"issue":"8","key":"3430_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/1751-2980.12271","volume":"16","author":"P Bai","year":"2015","unstructured":"Bai P, Zhou LY, Xiao XM, Luo Y, Ding Y (2015) Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. J Dig Dis 16(8):464\u2013470. https:\/\/doi.org\/10.1111\/1751-2980.12271","journal-title":"J Dig Dis"},{"issue":"6","key":"3430_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.5009\/gnl20242","volume":"15","author":"S Sue","year":"2021","unstructured":"Sue S, Maeda S (2021) Is a potassium-competitive acid blocker truly superior to proton pump inhibitors in terms of Helicobacter pylori eradication? Gut Liver 15(6):799\u2013810. https:\/\/doi.org\/10.5009\/gnl20242","journal-title":"Gut Liver"},{"issue":"2","key":"3430_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2169\/internalmedicine.2521-18","volume":"59","author":"S Kiyotoki","year":"2020","unstructured":"Kiyotoki S, Nishikawa J, Sakaida I (2020) Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med 59(2):153\u2013161. https:\/\/doi.org\/10.2169\/internalmedicine.2521-18","journal-title":"Intern Med"},{"issue":"7","key":"3430_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, Yoneyama T, Ashida K, Ogama Y, Warrington S (2015) Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41(7):636\u2013648. https:\/\/doi.org\/10.1111\/apt.13121","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3430_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/apt.14130","volume":"46","author":"YS Jung","year":"2017","unstructured":"Jung YS, Kim EH, Park CH (2017) Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 46(2):106\u2013114. https:\/\/doi.org\/10.1111\/apt.14130","journal-title":"Aliment Pharmacol Ther"},{"key":"3430_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13637","author":"C Yang","year":"2022","unstructured":"Yang C, Li S, Huang T, Lin H, Jiang Z, He Y, Yuan J, An H (2022) Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. https:\/\/doi.org\/10.1111\/jcpt.13637","journal-title":"J Clin Pharm Ther"},{"key":"3430_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"issue":"9","key":"3430_CR15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M (2016) Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65(9):1439\u20131446. https:\/\/doi.org\/10.1136\/gutjnl-2015-311304","journal-title":"Gut"},{"key":"3430_CR16","doi-asserted-by":"publisher","first-page":"4385161","DOI":"10.1155\/2017\/4385161","volume":"2017","author":"M Maruyama","year":"2017","unstructured":"Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, Imai R, Fujisawa T, Mori H, Matsuda Y, Wada S, Horiuchi A, Kiyosawa K (2017) Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol 2017:4385161. https:\/\/doi.org\/10.1155\/2017\/4385161","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"2","key":"3430_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12456","volume":"23","author":"S Sue","year":"2018","unstructured":"Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, Komatsu K, Kaneko H, Tamura T, Sasaki T, Kondo M, Shibata W, Maeda S (2018) Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter 23(2):e12456. https:\/\/doi.org\/10.1111\/hel.12456","journal-title":"Helicobacter"},{"key":"3430_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15837","author":"X Hou","year":"2022","unstructured":"Hou X, Meng F, Wang J, Sha W, Chiu CT, Chung WC, Gu L, Kudou K, Chong CF, Zhang S (2022) Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. J Gastroenterol Hepatol. https:\/\/doi.org\/10.1111\/jgh.15837","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"3430_CR19","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1111\/jgh.15700","volume":"36","author":"C Bunchorntavakul","year":"2021","unstructured":"Bunchorntavakul C, Buranathawornsom A (2021) Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. J Gastroenterol Hepatol 36(12):3308\u20133313. https:\/\/doi.org\/10.1111\/jgh.15700","journal-title":"J Gastroenterol Hepatol"},{"key":"3430_CR20","doi-asserted-by":"publisher","unstructured":"Zuberi BF, Ali FS, Rasheed T, Bader N, Hussain SM, Saleem A (2022) Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for Helicobacter pylori eradication: a randomized control trial. Pak J Med Sci 38 (4Part-II):965\u2013969. https:\/\/doi.org\/10.12669\/pjms.38.4.5436","DOI":"10.12669\/pjms.38.4.5436"},{"key":"3430_CR21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.05.055","author":"WD Chey","year":"2022","unstructured":"Chey WD, Megraud F, Laine L, Lopez LJ, Hunt BJ, Howden CW (2022) Vonoprazan triple and dual therapy for Helicobacter pylori infection in the US and Europe: randomized clinical trial. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2022.05.055","journal-title":"Gastroenterology"},{"key":"3430_CR22","doi-asserted-by":"publisher","unstructured":"Dong SQ, Singh TP, Wei X, Yao H, Wang HL (2017) Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: is superiority an illusion? Helicobacter 22(6). https:\/\/doi.org\/10.1111\/hel.12438","DOI":"10.1111\/hel.12438"},{"key":"3430_CR23","doi-asserted-by":"publisher","first-page":"9781212","DOI":"10.1155\/2019\/9781212","volume":"2019","author":"QJ Lyu","year":"2019","unstructured":"Lyu QJ, Pu QH, Zhong XF, Zhang J (2019) Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int 2019:9781212. https:\/\/doi.org\/10.1155\/2019\/9781212","journal-title":"Biomed Res Int"},{"key":"3430_CR24","doi-asserted-by":"publisher","unstructured":"Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, Suzuki H, Handa O, Furuta T, Mabe K, Murakami K, Sugiyama T, Uemura N, Takahashi S (2019) Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition. Helicobacter 24(4):e12597. https:\/\/doi.org\/10.1111\/hel.12597","DOI":"10.1111\/hel.12597"},{"issue":"5","key":"3430_CR25","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/jgh.15252","volume":"36","author":"DY Graham","year":"2021","unstructured":"Graham DY, Lu H, Shiotani A (2021) Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol 36(5):1159\u20131163. https:\/\/doi.org\/10.1111\/jgh.15252","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"3430_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12475","volume":"23","author":"Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH, Chinese Society of Gastroenterology CSGoHp, Peptic U","year":"2018","unstructured":"Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH, Chinese Society of Gastroenterology CSGoHp, Peptic U (2018) Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 23(2):e12475. https:\/\/doi.org\/10.1111\/hel.12475","journal-title":"Helicobacter"},{"issue":"11\u201312","key":"3430_CR27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/j.1600-0463.2004.apm11211-1211.x","volume":"112","author":"JL Simala-Grant","year":"2004","unstructured":"Simala-Grant JL, Taylor DE (2004) Molecular biology methods for the characterization of Helicobacter pylori infections and their diagnosis. APMIS 112(11\u201312):886\u2013897. https:\/\/doi.org\/10.1111\/j.1600-0463.2004.apm11211-1211.x","journal-title":"APMIS"},{"issue":"4","key":"3430_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12714","volume":"25","author":"Y Zou","year":"2020","unstructured":"Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, An Y, Yuan R, Wang Y, Xie Y (2020) The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis. Helicobacter 25(4):e12714. https:\/\/doi.org\/10.1111\/hel.12714","journal-title":"Helicobacter"},{"issue":"2","key":"3430_CR29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/gutjnl-2016-311796","volume":"66","author":"DY Graham","year":"2017","unstructured":"Graham DY (2017) Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut 66(2):384\u2013386. https:\/\/doi.org\/10.1136\/gutjnl-2016-311796","journal-title":"Gut"},{"issue":"1","key":"3430_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM, European H, Microbiota Study G, Consensus p","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM, European H, Microbiota Study G, Consensus P (2017) Management of Helicobacter pylori infection\u2014the Maastricht V\/Florence Consensus Report. Gut 66(1):6\u201330. https:\/\/doi.org\/10.1136\/gutjnl-2016-312288","journal-title":"Gut"},{"key":"3430_CR31","doi-asserted-by":"publisher","unstructured":"Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK (2016) The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 151(1):51\u201369 e14. https:\/\/doi.org\/10.1053\/j.gastro.2016.04.006","DOI":"10.1053\/j.gastro.2016.04.006"},{"key":"3430_CR32","doi-asserted-by":"publisher","unstructured":"McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP (2012) Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 36(5):414\u2013425.\u00a0https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05211.x","DOI":"10.1111\/j.1365-2036.2012.05211.x"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03430-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03430-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T08:05:02Z","timestamp":1674720302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03430-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3430"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03430-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]},"assertion":[{"value":"26 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics statement is not needed for this type of study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}